DGAP-News

4SC AG: 4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC 205 in China

DGAP-News: 4SC AG / Key word(s): Alliance
4SC AG: 4SC enters into licensing and development partnership with Link
Health for the cancer compound 4SC 205 in China

31.05.2016 / 07:30
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

4SC enters into licensing and development partnership with Link Health for
the cancer compound 4SC-205 in China

Link Health will be responsible for clinical development and regulatory
process for 4SC-205 in China whereas 4SC will receive upfront, milestone
and royalty payments

Planegg-Martinsried, Germany / Guangzhou, China, 31 May 2016 - 4SC AG (4SC,
FSE Prime Standard: VSC) has entered into a licensing and development
partnership for the cancer compound 4SC-205 with Guangzhou LingSheng Pharma
Tech Co., Ltd (Link Health). Link Health will receive the exclusive
licensing rights for the development and marketing of 4SC-205 in China,
Hong Kong, Taiwan and Macao. In return, Link Health will be responsible for
performing and financing the clinical development of 4SC-205.

After successfully completing the clinical studies, Link Health will be
responsible for regulatory approval at the CFDA (China Food and Drug
Administration) and regional product marketing. The data generated may be
used by 4SC to support further development of 4SC-205 in other key markets,
such as Europe or the US.

Under the agreement, 4SC will receive upfront and milestone payments
totaling up to EUR 76 million from Link Health payable upon achieving
specified development, regulatory and commercialization milestones. In
addition, 4SC will be eligible to double-digit royalties linked to product
sales of 4SC-205 in China.

"We are very pleased to partner with Link Health having in-depth expertise
in the clinical development, approval process and marketing of oncology
products in this important Asian market," comments Enno Spillner, CEO & CFO
of 4SC. "Having shown promising results in the Phase I study in patients
with advanced cancer, this partnership is an important step to ensure
efficient further development of the cancer drug 4SC-205. On the other
hand, in line with its strategic focus, 4SC can use its own financial
resources for development of the epigenetic products resminostat and
4SC-202. In parallel, we are looking for further development and licensing
opportunities for 4SC-205."

Dr Yan Song, CEO of Link Health, says: "We are proud to be given the
opportunity to take over this innovative cancer product for our region and
are planning an extensive clinical development program. Thanks to the
promising preclinical and clinical data on 4SC-205, we have high hopes for